Trial Profile
An Open-Label, Single-Center, Parallel Group Study to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Injection in Heart Failure Patients on Standard Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jul 2013
Price :
$35
*
At a glance
- Drugs Recombinant human neuregulin 1-beta (Primary)
- Indications Chronic heart failure
- Focus Biomarker; Registrational; Therapeutic Use
- 24 May 2013 Results published.
- 24 May 2013 New trial record
- 23 May 2013 Pooled phase II results published in a Zensun Sci & Tech media release.